Journal
PHARMACOGENETICS AND GENOMICS
Volume 26, Issue 2, Pages 100-102Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FPC.0000000000000191
Keywords
rs924607; CEP72; neurotoxicity; vincristine
Funding
- Spanish Thematic Network of Cooperative Investigation in Cancer RTICC [RD/12/0036/0036, RD/12/0036/0060]
- Basque Government [IT661-13, 2012111053]
- University of the Basque Country UPV/EHU [UFI11/35]
- Basque Government
Ask authors/readers for more resources
Vincristine is a component of acute lymphoblastic leukemia (ALL) treatment with the potential to induce peripheral neuropathy. Recently, the CEP72 rs924607 TT genotype was found to be associated with vincristine-induced toxicity during the continuation phase in pediatric ALL patients treated on the Total XIIIB and COG AALL0433 protocols at St Jude Children's Research Hospital and Children's Oncology Group. This finding could provide a base for safer dosing of vincristine. Nevertheless, there are variations in vincristine regimens among ALL treatment protocols and phases in different populations. Therefore, the aim of this study was to determine whether the CEP72 rs924607 TT genotype is a useful marker of vincristine neuropathy during induction therapy among Spanish children with B-ALL treated on the LAL-SHOP protocols. No association was found between neurotoxicity during the induction phase and the rs924607 TT genotype. This lack of association could be because of population differences and/or differences in neurotoxicity etiology between induction and continuation phases of treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available